The Body Shop IV Infusion Therapy
Pump Up the Protein Who knew that your favorite lean proteins like poultry, fish, beans, and tofu were also GLP-1 superstars
MedComm 4 , e298 (2023)
Key Takeaways Cagrilintide is a long-acting amylin analogue with clinical trial doses ranging from 0.3 mg to 4.5 mg weekly, while retatrutide is a triple agonist studied at 4 mg, 8 mg, and 12 mg weekly doses No published clinical trials currently exist evaluating the cagrilintide dosage with retatrutide combination, making any combined use experimental and off-label Both peptides work through different mechanismscagrilintide activates amylin receptors while retatrutide targets GIP, GLP-1, and glucagon receptorssuggesting potential complementary effects Gastrointestinal side effects (nausea, vomiting) occur in 60-80% of participants at higher doses for both compounds, raising concerns about additive effects when combined Proper dose escalation protocols spanning 8-20 weeks are critical for tolerability and adherence in peptide-based metabolic therapies Understanding Cagrilintide: Mechanism and Dosage Fundamentals What Is Cagrilintide
Remove the blue flip-off seal from the BSS PLUS Part II (20 mL) vial
Trulicity and Ozempic are both GLP-1 receptor agonists used to manage type 2 diabetes, but Ozempic is also approved for weight loss and has shown greater efficacy in lowering blood sugar levels and promoting weight reduction in clinical studies
